Kenvue Inc. (NYSE:KVUE) Receives $20.23 Average Price Target from Analysts

Shares of Kenvue Inc. (NYSE:KVUE) have received an average recommendation of “Hold” from the nineteen analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation, twelve have issued a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $20.2333.

KVUE has been the topic of a number of recent analyst reports. The Goldman Sachs Group lowered their target price on shares of Kenvue from $22.00 to $19.00 and set a “neutral” rating on the stock in a report on Thursday, October 2nd. Evercore ISI set a $18.00 price objective on shares of Kenvue in a research note on Tuesday, October 28th. Royal Bank Of Canada cut their target price on shares of Kenvue from $24.00 to $22.00 and set a “sector perform” rating for the company in a research note on Friday, August 8th. Weiss Ratings reiterated a “hold (c-)” rating on shares of Kenvue in a report on Tuesday, October 14th. Finally, Barclays upped their price objective on Kenvue from $17.00 to $18.00 and gave the company an “equal weight” rating in a research note on Monday, November 10th.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in KVUE. CWM LLC lifted its holdings in shares of Kenvue by 17.2% during the first quarter. CWM LLC now owns 29,342 shares of the company’s stock worth $704,000 after buying an additional 4,309 shares in the last quarter. Signaturefd LLC increased its position in Kenvue by 112.1% during the first quarter. Signaturefd LLC now owns 8,315 shares of the company’s stock worth $199,000 after acquiring an additional 4,395 shares during the period. Apollon Wealth Management LLC raised its stake in Kenvue by 35.7% in the 1st quarter. Apollon Wealth Management LLC now owns 15,875 shares of the company’s stock worth $381,000 after purchasing an additional 4,174 shares in the last quarter. Wealthfront Advisers LLC boosted its holdings in Kenvue by 114.4% in the 1st quarter. Wealthfront Advisers LLC now owns 54,233 shares of the company’s stock valued at $1,301,000 after purchasing an additional 28,941 shares during the period. Finally, Victory Capital Management Inc. grew its position in shares of Kenvue by 0.6% during the 1st quarter. Victory Capital Management Inc. now owns 1,646,017 shares of the company’s stock worth $39,471,000 after purchasing an additional 9,079 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.

Kenvue Stock Performance

KVUE opened at $16.27 on Friday. The business’s 50-day simple moving average is $16.37 and its 200 day simple moving average is $19.98. Kenvue has a 52-week low of $14.02 and a 52-week high of $25.17. The company has a debt-to-equity ratio of 0.66, a quick ratio of 0.69 and a current ratio of 0.98. The firm has a market capitalization of $31.17 billion, a PE ratio of 21.70, a PEG ratio of 2.43 and a beta of 0.71.

Kenvue (NYSE:KVUE) last posted its quarterly earnings results on Monday, November 3rd. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.01. Kenvue had a return on equity of 20.02% and a net margin of 9.55%.The firm had revenue of $3.76 billion for the quarter, compared to analyst estimates of $3.83 billion. During the same quarter in the previous year, the firm earned $0.28 EPS. The business’s quarterly revenue was down 3.5% on a year-over-year basis. Kenvue has set its FY 2025 guidance at 1.000-1.050 EPS. As a group, sell-side analysts expect that Kenvue will post 1.14 earnings per share for the current fiscal year.

Kenvue Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Wednesday, November 26th. Stockholders of record on Wednesday, November 12th will be paid a dividend of $0.2075 per share. The ex-dividend date is Wednesday, November 12th. This represents a $0.83 dividend on an annualized basis and a dividend yield of 5.1%. Kenvue’s dividend payout ratio (DPR) is 110.67%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.